Patient perspective on watchful waiting/active surveillance for localized prostate cancer

Journal of the American Board of Family Medicine

Volumn 25, Issue 6, 2012, Pages 763-770

  Xu, Jinping ^a   Neale, Anne Victoria ^a   Dailey, Rhonda K ^a   Eggly, Susan ^a   Schwartz, Kendra L ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Active surveillance; Decision making; Medical oncology; Prostate cancer; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ANXIETY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; FEAR; GLEASON SCORE; HEALTH BELIEF; HUMAN; MALE; PATIENT ATTITUDE; PATIENT COUNSELING; PATIENT DECISION MAKING; PATIENT EDUCATION; PERSUASIVE COMMUNICATION; PROSTATE CANCER; PSYCHOSOCIAL CARE; SELF EVALUATION; SEMI STRUCTURED INTERVIEW; WATCHFUL WAITING;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; DECISION MAKING; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERVIEWS AS TOPIC; MALE; MICHIGAN; MIDDLE AGED; PATIENT PREFERENCE; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84869211119     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2012.06.120128     Document Type: Article

References (55)

1. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostatespecific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101:1325-9.
2. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.
3. Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics. PSA doubling times, and outcome. Eur Urol 2007;51:1244-51. (Pubitemid 46436308)
4. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78. (Pubitemid 36833878)
5. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.
6. Heijnsdijk EA, der Kinderen A, Wever EM, et al. Overdetection, overtreatment and costs in prostatespecific antigen screening for prostate cancer. Br J Cancer 2009;101:1833-8.
7. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
8. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9. (Pubitemid 38725420)
9. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
10. Stattin P, Holmberg E, Johansson JE, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010;102:950-8.
11. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009;302:1202-9.
12. Harlan SR, Cooperberg MR, Elkin EP, et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 2003;170:1804-7. (Pubitemid 37254932)
13. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lowerrisk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134-41. (Pubitemid 44288788)
14. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117-23.
15. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early stage prostate cancer: review of the current literature. Cancer 2008;112:1650-9. (Pubitemid 351536825)
16. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-9. (Pubitemid 46211550)
17. Allaf ME, Carter HB. Update on watchful waiting for prostate cancer. Curr Opin Urol 2004;14:171-5. (Pubitemid 38582316)
18. Bailey DE Jr, Wallace M. Critical review: is watchful waiting a viable management option for older men with prostate cancer? Am J Mens Health 2007;1:18-28.
19. Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431-6. (Pubitemid 29117315)
20. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004;5:101-6. (Pubitemid 38145893)
21. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106-31. (Pubitemid 46726449)
22. Chapple A, Ziebland S, Herxheimer A, et al. Is "watchful waiting" a real choice for men with prostate cancer? A qualitative study. BJU Int 2002;90:257-64. (Pubitemid 34989073)
23. Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med 2000;15:694-701.
24. Schwartz K, Powell IJ, Underwood W 3rd, et al. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology 2009;74:1296-302.
25. Shavers VL, Brown ML, Potosky AL, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med 2004;19:146-55. (Pubitemid 38368463)
26. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001;93:1864-71. (Pubitemid 34048653)
27. Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol 2005;23:7881-8. (Pubitemid 46657386)
28. Steenland K, Goodman M, Liff J, et al. The effect of race and rural residence on prostate cancer treatment choice among men in Georgia. Urology 2011;77:581-7.
29. Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 2006;106:1865-74. (Pubitemid 43673200)
30. Steenland K, Goodman M, Liff J, et al. Quality of life among men with prostate cancer in rural Georgia. Urology 2011;77:927-33.
31. Katz SJ, Lantz PM, Janz NK, et al. Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol 2005;23:5526-33.
32. Hu JC, Kwan L, Krupski TL, et al. Determinants of treatment regret in low-income, uninsured men with prostate cancer. Urology 2008;72:1274-9.
33. Xu J, Dailey RK, Eggly S, et al. Men's perspectives on selecting their prostate cancer treatment. JNMA 2011;103:468-78.
34. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q 1988;15:175-83.
35. Miller SM, Diefenbach MA. The Cognitive-Social Health Information Processing (C-SHIP) model: a theoretical framework for research in behavioral oncology. In Krantz DS, Baum A (eds). Technology and Methods in Behavioral Medicine. Mahwah, NJ: Lawrence Erlbaum; 1998:219-44.
36. Miller WL, Crabtree BF. Clinical research: a multimethod typology and qualitative roadmap. In Crabtree BF, MillerWL(eds). Doing qualitative research. 2nd edition. Thousand Oaks: Sage Publications; 1999;3-30.
37. Strauss A CJ. Basics of qualitative research: grounded theory procedures and techniques. Newbury Park: Sage Publications; 1990.
38. Lin K, Croswell JM, Koenig H, Lam C, Maltz A. Prostate-specific antigen-based screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Evidence synthesis number 90. AHRQ Publication No. 12-05160-EF-1. October 2011. Available at http://www. uspreventiveservicestaskforce.org/uspstf12/prostate/prcascres.pdf. Accessed September 11, 2012.
39. Harris G. U.S. panel says no to prostate screening for healthy men [press release online]. New York Times. October 6, 2011. Available at http://www.nytimes.com/2011/10/07/health/07prostate.html. Accessed October 14 2011.
40. Carroll PR. Early stage prostate cancer - do we have a problem with over-detection, overtreatment or both? J Urol 2005;173:1061-2.
41. National Institutes of Health State-of-the-Science Conference Statement. The role of active surveillance in the management of men with localized prostate cancer. Available at http://consensus.nih.gov/2011/docs/prostate/ ASPC%20Final%20Draft%20Statement.pdf. Accessed January 6, 2012.
42. O'Rourke ME. Narrowing the options: the process of deciding on prostate cancer treatment. Cancer Invest 1999;17:349-59. (Pubitemid 29266708)
43. Davison BJ, Oliffe JL, Pickles T, Mroz L. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum 2009;36:89-96.
44. Gorin MA, Soloway CT, Eldefrawy A, Soloway MS. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology 2011;77:588-91.
45. Demark-Wahnefried W, Schildkraut JM, Iselin CE, et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer 1998;83:320-30. (Pubitemid 28317812)
46. Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996;155:1667-73. (Pubitemid 26126973)
47. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004;22:439-45. (Pubitemid 41079772)
48. Freedland SJ, Jalkut M, Dorey F, et al. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology 2000;56:87-91. (Pubitemid 30408660)
49. Resnick MJ, Canter DJ, Guzzo TJ, et al. Does race affect postoperative outcomes in patients with lowrisk prostate cancer who undergo radical prostatectomy? Urology 2009;73:620-3.
50. McVey GP, McPhail S, Fowler S, et al. Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int 2010;106:1161-4.
51. Payer L. Medicine and culture: varieties of treatment in the United States, England, West Germany, and France. New York: Henry Holt and Company; 1996.
52. National Cancer Institute. National Cancer Act of 1971. Available at http://dtp.nci.nih.gov/timeline/noflash/milestones/M4Nixon.htm. Accessed November 12, 2011.
53. American Cancer Society. Cancer facts & figures 2011. Available at http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-factsfigures-2011. Accessed December 11, 2011.
54. Denberg TD, Melhado TV, Steiner JF. Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote. Cancer 2006;107:620-30. (Pubitemid 44107224)
55. Berry DL, Ellis WJ, Woods NF, et al. Treatment decision-making by men with localized prostate cancer: the influence of personal factors. Urol Oncol 2003;21:93-100. (Pubitemid 41123432)